- call +1-201-465-4211
- email sales@mrinsights.biz
Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease.
Scope of the Report:
This report studies the Diabetic Retinopathy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Diabetic Retinopathy market by product type and applications/end industries.
Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.
The global Diabetic Retinopathy market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Diabetic Retinopathy.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bayer
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
Actavis
Alimera Sciences
Ampio Pharmaceuticals
Antisense Therapeutics
BCN Peptides
Boehringer Ingelheim
Glycadia
iCo Therapeutics
Isis Pharmaceuticals
Kowa Group
Lpath
Numoda Capital
Ohr Pharmaceutical
OPKO Health
Parexel International
Promedior
pSivida
Quark Pharmaceuticals
R-Tech Ueno
Sirnaomics
ThromboGenics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Laser surgery
Injection of corticosteroids
Anti-VEGF drugs into the eye
Vitrectomy
Market Segment by Applications, can be divided into
Hospitals
Clinics and laboratories
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Diabetic Retinopathy Market Overview
1.1 Product Overview and Scope of Diabetic Retinopathy
1.2 Classification of Diabetic Retinopathy by Types
1.2.1 Global Diabetic Retinopathy Revenue Comparison by Types (2017-2023)
1.2.2 Global Diabetic Retinopathy Revenue Market Share by Types in 2017
1.2.3 Laser surgery
1.2.4 Injection of corticosteroids
1.2.5 Anti-VEGF drugs into the eye
1.2.6 Vitrectomy
1.3 Global Diabetic Retinopathy Market by Application
1.3.1 Global Diabetic Retinopathy Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics and laboratories
1.3.4 Others
1.4 Global Diabetic Retinopathy Market by Regions
1.4.1 Global Diabetic Retinopathy Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Diabetic Retinopathy Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Diabetic Retinopathy Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Diabetic Retinopathy Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Diabetic Retinopathy Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Diabetic Retinopathy Status and Prospect (2013-2023)
1.5 Global Market Size of Diabetic Retinopathy (2013-2023)
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Diabetic Retinopathy Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bayer Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.2 F. Hoffmann-La Roche
2.2.1 Business Overview
2.2.2 Diabetic Retinopathy Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 F. Hoffmann-La Roche Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Diabetic Retinopathy Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.4 Regeneron Pharmaceuticals
2.4.1 Business Overview
2.4.2 Diabetic Retinopathy Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Regeneron Pharmaceuticals Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.5 Actavis
2.5.1 Business Overview
2.5.2 Diabetic Retinopathy Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Actavis Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.6 Alimera Sciences
2.6.1 Business Overview
2.6.2 Diabetic Retinopathy Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Alimera Sciences Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.7 Ampio Pharmaceuticals
2.7.1 Business Overview
2.7.2 Diabetic Retinopathy Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Ampio Pharmaceuticals Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.8 Antisense Therapeutics
2.8.1 Business Overview
2.8.2 Diabetic Retinopathy Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Antisense Therapeutics Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.9 BCN Peptides
2.9.1 Business Overview
2.9.2 Diabetic Retinopathy Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 BCN Peptides Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.10 Boehringer Ingelheim
2.10.1 Business Overview
2.10.2 Diabetic Retinopathy Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Boehringer Ingelheim Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.11 Glycadia
2.11.1 Business Overview
2.11.2 Diabetic Retinopathy Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Glycadia Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.12 iCo Therapeutics
2.12.1 Business Overview
2.12.2 Diabetic Retinopathy Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 iCo Therapeutics Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.13 Isis Pharmaceuticals
2.13.1 Business Overview
2.13.2 Diabetic Retinopathy Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Isis Pharmaceuticals Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.14 Kowa Group
2.14.1 Business Overview
2.14.2 Diabetic Retinopathy Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Kowa Group Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.15 Lpath
2.15.1 Business Overview
2.15.2 Diabetic Retinopathy Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Lpath Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.16 Numoda Capital
2.16.1 Business Overview
2.16.2 Diabetic Retinopathy Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Numoda Capital Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.17 Ohr Pharmaceutical
2.17.1 Business Overview
2.17.2 Diabetic Retinopathy Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Ohr Pharmaceutical Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.18 OPKO Health
2.18.1 Business Overview
2.18.2 Diabetic Retinopathy Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 OPKO Health Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.19 Parexel International
2.19.1 Business Overview
2.19.2 Diabetic Retinopathy Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Parexel International Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.20 Promedior
2.20.1 Business Overview
2.20.2 Diabetic Retinopathy Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Promedior Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.21 pSivida
2.21.1 Business Overview
2.2.2 Diabetic Retinopathy Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 pSivida Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.22 Quark Pharmaceuticals
2.22.1 Business Overview
2.22.2 Diabetic Retinopathy Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Quark Pharmaceuticals Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.23 R-Tech Ueno
2.23.1 Business Overview
2.23.2 Diabetic Retinopathy Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 R-Tech Ueno Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.24 Sirnaomics
2.24.1 Business Overview
2.24.2 Diabetic Retinopathy Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Sirnaomics Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
2.25 ThromboGenics
2.25.1 Business Overview
2.25.2 Diabetic Retinopathy Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 ThromboGenics Diabetic Retinopathy Revenue, Gross Margin and Market Share (2016-2017)
3 Global Diabetic Retinopathy Market Competition, by Players
3.1 Global Diabetic Retinopathy Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Diabetic Retinopathy Players Market Share
3.2.2 Top 10 Diabetic Retinopathy Players Market Share
3.3 Market Competition Trend
4 Global Diabetic Retinopathy Market Size by Regions
4.1 Global Diabetic Retinopathy Revenue and Market Share by Regions
4.2 North America Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
4.3 Europe Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
4.5 South America Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
5 North America Diabetic Retinopathy Revenue by Countries
5.1 North America Diabetic Retinopathy Revenue by Countries (2013-2018)
5.2 USA Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
5.3 Canada Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
5.4 Mexico Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
6 Europe Diabetic Retinopathy Revenue by Countries
6.1 Europe Diabetic Retinopathy Revenue by Countries (2013-2018)
6.2 Germany Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
6.3 UK Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
6.4 France Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
6.5 Russia Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
6.6 Italy Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Diabetic Retinopathy Revenue by Countries
7.1 Asia-Pacific Diabetic Retinopathy Revenue by Countries (2013-2018)
7.2 China Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
7.3 Japan Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
7.4 Korea Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
7.5 India Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
8 South America Diabetic Retinopathy Revenue by Countries
8.1 South America Diabetic Retinopathy Revenue by Countries (2013-2018)
8.2 Brazil Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
8.3 Argentina Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
8.4 Colombia Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Diabetic Retinopathy by Countries
9.1 Middle East and Africa Diabetic Retinopathy Revenue by Countries (2013-2018)
9.2 Saudi Arabia Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
9.3 UAE Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
9.4 Egypt Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
9.5 Nigeria Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
9.6 South Africa Diabetic Retinopathy Revenue and Growth Rate (2013-2018)
10 Global Diabetic Retinopathy Market Segment by Type
10.1 Global Diabetic Retinopathy Revenue and Market Share by Type (2013-2018)
10.2 Global Diabetic Retinopathy Market Forecast by Type (2018-2023)
10.3 Laser surgery Revenue Growth Rate (2013-2023)
10.4 Injection of corticosteroids Revenue Growth Rate (2013-2023)
10.5 Anti-VEGF drugs into the eye Revenue Growth Rate (2013-2023)
10.6 Vitrectomy Revenue Growth Rate (2013-2023)
11 Global Diabetic Retinopathy Market Segment by Application
11.1 Global Diabetic Retinopathy Revenue Market Share by Application (2013-2018)
11.2 Diabetic Retinopathy Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics and laboratories Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Diabetic Retinopathy Market Size Forecast (2018-2023)
12.1 Global Diabetic Retinopathy Market Size Forecast (2018-2023)
12.2 Global Diabetic Retinopathy Market Forecast by Regions (2018-2023)
12.3 North America Diabetic Retinopathy Revenue Market Forecast (2018-2023)
12.4 Europe Diabetic Retinopathy Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Diabetic Retinopathy Revenue Market Forecast (2018-2023)
12.6 South America Diabetic Retinopathy Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Diabetic Retinopathy Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Diabetic Retinopathy Picture
Table Product Specifications of Diabetic Retinopathy
Table Global Diabetic Retinopathy and Revenue (Million USD) Market Split by Product
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
